IP Library Granted Patent US 9,266,861
Granted Patent B2
US 9,266,861 · App. 14/660,720 · Granted Feb 23, 2016

Method of synthesizing thyroid hormone analogs and polymorphs thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,266,861
App. No.
14/660,720
Granted
Feb 23, 2016
Kind
B2
Abstract

The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

Claims (34)

1. A morphic form of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (“Compound A”) (Form I) characterized by an X-ray powder diffraction pattern including peaks at about 10.5, 18.7, 22.9, 23.6, and 24.7 degrees 2θ.

2. The morphic form of claim 1 characterized by an X-ray powder diffraction pattern further including peaks at about 8.2, 11.2, 15.7 16.4, 17.7, 30.0, and 32.2 degrees 2θ.

3. The morphic form of claim 1 characterized by an X-ray powder diffraction pattern substantially similar to that set forth in FIG. 1 .

4. The morphic form of claim 1 , wherein the morphic form has a purity of 95% or greater.

5. A pharmaceutical composition comprising a morphic form of claim 1 and a pharmaceutically acceptable carrier.

6. A synthetic process comprising:

(a) contacting R 1 MgX or R 1 Li with a compound of Formula (I):

 to form a compound of Formula (II):

 in which R 1 is isopropyl or isopropenyl, X is halo and R 2 is H or an amine protecting group; and

(b) converting the compound of Formula (II) to a compound of Formula (III):

 in the presence of a base when R 1 is isopropenyl or in the presence of an oxidizing agent when R 1 is isopropyl.

7. The process of claim 6 , further comprising: (c), when present, removing the amine protecting group R 2 of the compound of Formula (III) to form 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one.

8. The process of claim 6 , wherein step (a) is performed by contacting R 1 MgX with the compound of Formula (I), in which R 1 is isopropenyl and X is Br; or step (a) is performed by contacting R 1 MgX with the compound of Formula (I), in which R 1 is isopropyl and X is Cl.

9. The process of claim 6 , wherein the oxidizing agent in step (b) is bromine and step (b) is performed in the presence of an acid.

10. The process of claim 6 , wherein R 2 is acetyl or benzoyl.

11. The process of claim 7 , further comprising: (d) converting 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one to 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (“Compound A”) by contacting 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one with ethyl (2-cyanoacetyl)carbamate and a metal nitrite followed by treatment with potassium acetate in DMAC.

12. A process of preparing the preparing the morphic form of claim 1 , the process comprising:

heating a mixture comprising a solvent and Compound A at a first temperature, and

cooling the mixture to a second temperature that is lower than the first temperature so as to obtain the morphic form of claim 1 , wherein the solvent is selected from ethanol, isopropanol, methyl isobutyl ketone and a combination thereof.

13. The process of claim 12 , wherein the first temperature is between about 60° C. and about 80° C.

14. The process of claim 12 , wherein the second temperature is between about 0° C. and about 60° C.

15. The process of claim 12 , wherein the solvent is ethanol or methyl isobutyl ketone.

16. A process of preparing a morphic form of claim 1 , the process comprising:

heating a mixture comprising a solvent and Compound A at a first temperature, wherein the solvent is selected from ethanol, isopropanol, methyl isobutyl ketone and a combination thereof;

cooling the mixture to a second temperature that is lower than the first temperature;

filtering the mixture to obtain a filter cake;

rinsing the filter cake with an organic solvent to obtain a rinsed filter cake; and

drying the rinsed filter cake to obtain the morphic form of claim 1 .

17. A process of preparing a morphic form of claim 1 , the process comprising:

heating a mixture comprising ethanol and Compound A at a first temperature;

cooling the mixture to a second temperature that is lower than the first temperature but greater than about 40° C.;

filtering the mixture at a temperature not lower than about 40° C. to obtain a filter cake;

rinsing the filter cake at a temperature not lower than about 40° C. with ethanol to obtain a rinsed filter cake; and

drying the rinsed filter cake at a temperature not lower than about 40° C. to obtain the morphic form of claim 1 .

Assignments (5)
SECURITY INTEREST Recorded Jul 17, 2025
From: MADRIGAL PHARMACEUTICALS, INC.
To: LSI FINANCING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 072038/0693 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF ASSIGNOR SHU'S FIRST NAME ON THE COVER SHEET PREVIOUSLY RECORDED PREVIOUSLY RECORDED ON REEL 35214 FRAME 632. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 16, 2024
From: CHOI, DUK SOON; SHU, LIANHE; WANG, PING
To: HOFFMANN-LA ROCHE, INC.
Reel/Frame 067126/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2015
From: CHOI, DUK SOON; SHU, LIANSHE; WANG, PING
To: HOFFMANN-LA ROCHE, INC.
Reel/Frame 035214/0632 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2015
From: HESTER II, D. KEITH; DUGUID, ROBERT J.; KELLY, MARTHA J.; CHASNOFF, ANNA; DONG, GANG; CROW, EDWIN L.; TAUB, REBECCA; REYNOLDS, CHARLES H.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 035214/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2015
From: HESTER II, D. KEITH; DUGUID, ROBERT J.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 035214/0864 →